Brief: HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
09/03/2026 11:00
March 9 (Reuters) - HUTCHMED (China) Ltd 0013.HK: HUTCHMED ANNOUNCES UPDATE ON LICENSED ONCOLOGY PRODUCT TAZVERIK® IN CHINA HUTCHMED (CHINA) LTD - IPSEN INITIATES WITHDRAWAL AND RECALL OF TAZVERIK IN CHINA HUTCHMED (CHINA) LTD - WITHDRAWS TAZVERIK IN CHINESE MAINLAND, HONG KONG, MACAU; ENDS ALL ACTIVE CLINICAL TRIALS HUTCHMED (CHINA) LTD: IPSEN HAS INFORMED HUTCHMED THAT IT IS VOLUNTARILY WITHDRAWING TAZVERIK IN US HUTCHMED (CHINA): WITHDRAWAL NOT EXPECTED TO IMPACT FINANCIAL GUIDANCE Source text: ID:nGNX9DC3pz Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients